<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35584816</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>377</Volume><PubDate><Year>2022</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study.</ArticleTitle><Pagination><StartPage>e069676</StartPage><MedlinePgn>e069676</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e069676</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj-2021-069676</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination.</AbstractText><AbstractText Label="DESIGN">Observational cohort study.</AbstractText><AbstractText Label="SETTING">Community dwelling population, UK.</AbstractText><AbstractText Label="PARTICIPANTS">28&#x2009;356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021.</AbstractText><AbstractText Label="RESULTS">Mean age of participants was 46 years, 55.6% (n=15&#x2009;760) were women, and 88.7% (n=25&#x2009;141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval -18.6% to -6.6%, P&lt;0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval -0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval -14.1% to -3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (-1.2% to -0.4% per week, P&lt;0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination.</AbstractText><AbstractText Label="CONCLUSIONS">The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayoubkhani</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6352-0394</Identifier><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, UK daniel.ayoubkhani@ons.gov.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermingham</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pouwels</LastName><ForeName>Koen B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glickman</LastName><ForeName>Myer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nafilyan</LastName><ForeName>Vah&#xe9;</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Health Analysis and Life Events Division, Office for National Statistics, Newport, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Public Health, Environment, and Society, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaccardi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwan</LastName><ForeName>Nisreen A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Applied Research Collaboration (ARC) Wessex, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>A Sarah</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2022 May 18;377:o988. doi: 10.1136/bmj.o988</RefSource><PMID Version="1">35584848</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; KK chairs the long covid research-funded group reporting to the Chief Medical Officer, chairs the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergencies (SAGE), and is a member of SAGE.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35584816</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>UK government. Coronavirus (COVID-19) in the UK. 18 February 2022. https://coronavirus.data.gov.uk
</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. www.nice.org.uk/guidance/ng188
</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 December 2021. 2021. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2december2021
</Citation></Reference><Reference><Citation>National Institute for Health Research. Living with Covid19 &#x2013; Second review. 2021. https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review
</Citation></Reference><Reference><Citation>
Ziauddeen N, Gurdasani D, O&#x2019;Hara ME, et al. . Characteristics of Long Covid: findings from a social media survey.
medRxiv
2021. www.medrxiv.org/content/10.1101/2021.03.21.21253968v2
10.1136/jech-2021-SSMabstracts.194
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.21.21253968v2</ArticleId><ArticleId IdType="doi">10.1136/jech-2021-SSMabstracts.194</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>
Whitaker M, Elliott J, Chadeau-Hyam M, et al. . Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508&#x2009;707 people.
medRxiv
2021. https://www.medrxiv.org/content/10.1101/2021.06.28.21259452v1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259452v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Sobieszczyk ME, Hirsch I, et al. AstraZeneca AZD1222 Clinical Study Group . Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021;385:2348-60. 10.1056/NEJMoa2105290.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, et al. Oxford COVID Vaccine Trial Group . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111. 10.1016/S0140-6736(20)32661-1.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-15. 10.1056/NEJMoa2034577.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. COVE Study Group . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-16. 10.1056/NEJMoa2035389.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard E, Matthews PC, Stoesser N, et al. . Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 2021;27:1370-8. 10.1038/s41591-021-01410-w.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01410-w</ArticleId><ArticleId IdType="pmc">PMC8363500</ArticleId><ArticleId IdType="pubmed">34108716</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Klaser K, May A, et al. . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939-49. 10.1016/S1473-3099(21)00224-3.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00224-3</ArticleId><ArticleId IdType="pmc">PMC8078878</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med 2021;385:759-60. 10.1056/NEJMc2107717.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107717</ArticleId><ArticleId IdType="pmc">PMC8262621</ArticleId><ArticleId IdType="pubmed">34161702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088. 10.1136/bmj.n1088.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Deaths involving COVID-19 by vaccination status, England: deaths occurring between 2 January and 24 September 2021. 2021. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19byvaccinationstatusengland/deathsoccurringbetween2januaryand24september2021
</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43-55. 10.1016/S1473-3099(21)00460-6.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>
Massey D, Berrent D, Akrami A, et al. . Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination. medRxiv
2021. www.medrxiv.org/content/10.1101/2021.07.21.21260391v2
10.1101/2021.07.21.21260391
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391v2</ArticleId><ArticleId IdType="doi">10.1101/2021.07.21.21260391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood O, Strain D, Rossman J. The impact of COVID vaccination on symptoms of Long Covid. An international survey of 900 people with lived experience. 2021. https://3ca26cd7-266e-4609-b25f-6f3d1497c4cf.filesusr.com/ugd/8bd4fe_a338597f76bf4279a851a7a4cb0e0a74.pdf
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>
Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are vaccines safe in patients with Long COVID? A prospective observational study.
medRxiv
2021. www.medrxiv.org/content/10.1101/2021.03.11.21253225v3
10.1101/2021.03.11.21253225
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21253225v3</ArticleId><ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France.
SSRN
2021. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3932953
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake E, Martin S. Long Covid: Online patient narratives, public health communication and vaccine hesitancy. Digit Health 2021;7:20552076211059649. 10.1177/20552076211059649.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20552076211059649</ArticleId><ArticleId IdType="pmc">PMC8638072</ArticleId><ArticleId IdType="pubmed">34868622</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. COVID-19 Infection Survey: methods and further information. 2021. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation
</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. . Characterising long COVID: a living systematic review. BMJ Glob Health 2021;6:e005427. 10.1136/bmjgh-2021-005427.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021. www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
</Citation></Reference><Reference><Citation>UK Government. COVID-19: the green book, chapter 14a. 2020. www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a
</Citation></Reference><Reference><Citation>Public Health England. COVID-19: the green book, chapter 14a. 2020. www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a
</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107. 10.1002/sim.3697.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2017;46:348-55. 10.1093/ije/dyw098.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw098</ArticleId><ArticleId IdType="pmc">PMC5407170</ArticleId><ArticleId IdType="pubmed">27283160</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) Infection Survey technical article: waves and lags of COVID-19 in England, June 2021. 2021. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticle/wavesandlagsofcovid19inenglandjune2021
</Citation></Reference><Reference><Citation>Centres for Disease Control and Prevention. Symptoms of COVID-19. 2021. www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
</Citation></Reference><Reference><Citation>Alwan NA. Lessons from Long COVID: working with patients to design better research. Nat Rev Immunol 2022;22:201-2. 10.1038/s41577-022-00692-6.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00692-6</ArticleId><ArticleId IdType="pmc">PMC8853146</ArticleId><ArticleId IdType="pubmed">35169259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA. The teachings of Long COVID. Commun Med 2021;1:15. 10.1038/s43856-021-00016-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-021-00016-0</ArticleId><ArticleId IdType="pmc">PMC9053272</ArticleId><ArticleId IdType="pubmed">35602198</ArticleId></ArticleIdList></Reference><Reference><Citation>
Massey D, Berrent D, Akrami A, et al. . Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination. medRxiv
2021. www.medrxiv.org/content/10.1101/2021.07.21.21260391v2
10.1101/2021.07.21.21260391
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391v2</ArticleId><ArticleId IdType="doi">10.1101/2021.07.21.21260391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, et al. . Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 2022;20:26. 10.1186/s12916-021-02228-6.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos AA, Pelechas E, Voulgari PV. Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity? Clin Rheumatol 2022;41:957-8. 10.1007/s10067-022-06092-4.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06092-4</ArticleId><ArticleId IdType="pmc">PMC8831874</ArticleId><ArticleId IdType="pubmed">35147823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639-44. 10.1038/s41586-021-03207-w.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, et al. . Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol 2021;41:1490-501. 10.1007/s10875-021-01083-7.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AJ, MacKenna B, Inglesby P, et al. The OpenSAFELY Collaborative ). Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract 2021;71:e806-14. 10.3399/BJGP.2021.0301.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP.2021.0301</ArticleId><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. 2021. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>